Compositions, devices, and methods for intranasal delivery of dry powder epinephrine
AssigneeBelhaven BioPharma Inc.
InventorsScott Lyman, Brian Taubenheim
Life of this patent
Estimating the term…
Abstract
Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).
Claims20
An apparatus for delivery of a dry powder pharmaceutical composition, the apparatus comprising:
- a reservoir containing a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof and a carrier, wherein the dry powder pharmaceutical composition has a bulk particle size distribution characterized by a Dv50 of between about 5 microns and about 30 microns;
- an air delivery assembly;
- and
- a delivery aperture;
- wherein upon actuation of the apparatus, the air delivery assembly is configured to produce an airflow through the reservoir to deliver a mixture of the airflow and the dose of the dry powder pharmaceutical composition via the delivery aperture, wherein the dry powder pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 100 microns and that is greater than the Dv50 of the bulk particle size distribution.
An apparatus for delivery of a dry powder pharmaceutical composition, the apparatus comprising:
- a reservoir containing a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof;
- an air delivery assembly;
- and
- a delivery aperture;
- wherein upon actuation of the apparatus, the air delivery assembly is configured to produce an airflow through the reservoir to deliver a mixture of the airflow and the dose of the dry powder pharmaceutical composition via the delivery aperture, wherein the dry powder pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 that is greater than the Dv50 of the bulk particle size distribution.
A dry powder pharmaceutical composition comprising:
- epinephrine or a pharmaceutically acceptable salt thereof;
- and
- a carrier;
- wherein the dry powder pharmaceutical composition has a bulk particle size distribution characterized by a Dv50 of between about 5 microns and about 30 microns;
- and
- wherein the dry powder pharmaceutical composition is formulated such that intranasal delivery of a dose of the dry powder pharmaceutical composition produces a spray having an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 100 microns and that is greater than the Dv50 of the bulk particle size distribution.
Dependencies are inferred from the claim text.